Tc 99m dianexin

Drug Profile

Tc 99m dianexin

Alternative Names: 99m-Tc-HYNIC annexin V; 99m-Tc-HYNIC dianexin; 99m-Tc-HYNIC-annexin A5; 99mTc-4,5-bis(thioacetamido)pentanoyl-annexin-V; 99mTc-BTAP-annexin-V; Apomate; Tc 99m annexin-V; Tc 99m-HYNIC annexin V; Technetium Tc 99m BTAP-annexin-V; Technetium Tc 99m HYNIC annexin V

Latest Information Update: 14 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Class Calcium binding proteins; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tissue degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Tissue degeneration

Most Recent Events

  • 07 Nov 2006 AnorMED has been acquired by Genzyme Corporation
  • 06 Jul 2004 North American Sicentific presented observations from an ongoing European clinical trial with Tc 99m dianexin in patients with non-small lung cancer
  • 14 Oct 2003 North American Scientific announced preliminary data from an ongoing European study with Tc 99m dianexin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top